FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040797730> ?p ?o ?g. }

• W2040797730 endingPage "518" @default.
• W2040797730 startingPage "512" @default.
• W2040797730 abstract "Background : Overexpression of Pglycoprotein, a transmembrane protein capable of transporting a broad spectrum of anticancer drugs out of cells, likely contributes to tumor drug resistance. Strategies for overcoming this resistance include the use of specific compounds, such as cyclosporin derivatives, that modulate P-glycoprotein function and antibodies that bind to the protein, thereby altering its activity. Purpose : We examined the antitumor activity of combination treatment with the anti-P-glycoprotein monoclonal antibody MRK-16, a cyclosporin derivative (either cyclosporin A [CsA] or PSC 833), and the anticancer drug Adriamycin (ADM) against human colorectal carcinoma cells in vitro and established xenografts of these cells in vivo. Methods : The human colorectal carcinoma cell line HCT-15 and its ADM-resistant subline HCT-15/ADM2-2 were used in this study. Cellular staining with a tetrazolium dye was used to assess the antitumor (i.e., antiproliferative) effects of treatment in vitro. Caliper measurement of tumor volumes was used to assess the antitumor effects of treatment in vivo. Cell surface binding of MRK16 was measured by means of an immunofluorescence assay. Differences in the patterns of tumor cell growth in vitro and tumor growth rates in vivo were evaluated by means of repeated measure analysis of variance. Synergy in the combined effects of treatment was evaluated by means of the fractional product method. Results : HCT15 cells were found to express P-glycoprotein intrinsically; HCT-15/ADM2-2 cells expressed approximately five times more P-glycoprotein than the parental cells. HCT-15/ADM2-2 cells were also found to be about eight times more resistant to ADM in vitro than the parental cells. Incubation of both cell types in vitro with either MRK-16 and ADM or one of the cyclosporin derivatives and ADM inhibited cell growth minimally; however, ternary treatment with MRK-16, one of the cyclosporin derivatives, and ADM dramatically reduced the growth of both cell types. An analysis of treatment effects indicated that synergistic effects were obtained with ternary treatment. When athymic mice bearing established tumors (either HCT-15 or HCT15/ ADM2-2) were treated similarly with various combinations of the tested agents, the most pronounced antitumor effects were observed with ternary treatment. In some mice bearing HCT15/ ADM2-2 xenografts, ternary treatment led to complete tumor regression. Finally, CsA and PSC 833 were both shown to enhance MRK-16 binding to HCT-15 cells and HCT-15/ADM2-2 cells in vitro. Conclusion : Combination treatment with a cyclosporin derivative and an anti-P-glycoprotein antibody can be effective in circumventing Pglycoprotein-mediated drug resistance." @default.
• W2040797730 created "2016-06-24" @default.
• W2040797730 creator A5010011336 @default.
• W2040797730 creator A5033231895 @default.
• W2040797730 creator A5034516816 @default.
• W2040797730 creator A5082394662 @default.
• W2040797730 date "1997-04-02" @default.
• W2040797730 modified "2023-09-26" @default.
• W2040797730 title "Regression of Established Tumors Expressing P-glycoprotein by Combinations of Adriamycin, Cyclosporin Derivatives, and MRK-16 Antibodies" @default.
• W2040797730 cites W1029507972 @default.
• W2040797730 cites W180852479 @default.
• W2040797730 cites W1965982638 @default.
• W2040797730 cites W2003117375 @default.
• W2040797730 cites W2005877531 @default.
• W2040797730 cites W2007956442 @default.
• W2040797730 cites W2009168842 @default.
• W2040797730 cites W2018577228 @default.
• W2040797730 cites W2029852535 @default.
• W2040797730 cites W2044974911 @default.
• W2040797730 cites W2063578373 @default.
• W2040797730 cites W2071657228 @default.
• W2040797730 cites W2093180739 @default.
• W2040797730 cites W2097878215 @default.
• W2040797730 cites W2107615796 @default.
• W2040797730 cites W2321867218 @default.
• W2040797730 doi "https://doi.org/10.1093/jnci/89.7.512" @default.
• W2040797730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9086008" @default.
• W2040797730 hasPublicationYear "1997" @default.
• W2040797730 type Work @default.
• W2040797730 sameAs 2040797730 @default.
• W2040797730 citedByCount "37" @default.
• W2040797730 countsByYear W20407977302012 @default.
• W2040797730 countsByYear W20407977302013 @default.
• W2040797730 countsByYear W20407977302014 @default.
• W2040797730 countsByYear W20407977302015 @default.
• W2040797730 countsByYear W20407977302017 @default.
• W2040797730 countsByYear W20407977302018 @default.
• W2040797730 countsByYear W20407977302019 @default.
• W2040797730 countsByYear W20407977302022 @default.
• W2040797730 countsByYear W20407977302023 @default.
• W2040797730 crossrefType "journal-article" @default.
• W2040797730 hasAuthorship W2040797730A5010011336 @default.
• W2040797730 hasAuthorship W2040797730A5033231895 @default.
• W2040797730 hasAuthorship W2040797730A5034516816 @default.
• W2040797730 hasAuthorship W2040797730A5082394662 @default.
• W2040797730 hasBestOaLocation W20407977301 @default.
• W2040797730 hasConcept C114851261 @default.
• W2040797730 hasConcept C133936738 @default.
• W2040797730 hasConcept C150903083 @default.
• W2040797730 hasConcept C153911025 @default.
• W2040797730 hasConcept C159654299 @default.
• W2040797730 hasConcept C202751555 @default.
• W2040797730 hasConcept C203014093 @default.
• W2040797730 hasConcept C207001950 @default.
• W2040797730 hasConcept C2778707650 @default.
• W2040797730 hasConcept C502942594 @default.
• W2040797730 hasConcept C542903549 @default.
• W2040797730 hasConcept C54355233 @default.
• W2040797730 hasConcept C55493867 @default.
• W2040797730 hasConcept C81885089 @default.
• W2040797730 hasConcept C86803240 @default.
• W2040797730 hasConcept C89423630 @default.
• W2040797730 hasConcept C98274493 @default.
• W2040797730 hasConceptScore W2040797730C114851261 @default.
• W2040797730 hasConceptScore W2040797730C133936738 @default.
• W2040797730 hasConceptScore W2040797730C150903083 @default.
• W2040797730 hasConceptScore W2040797730C153911025 @default.
• W2040797730 hasConceptScore W2040797730C159654299 @default.
• W2040797730 hasConceptScore W2040797730C202751555 @default.
• W2040797730 hasConceptScore W2040797730C203014093 @default.
• W2040797730 hasConceptScore W2040797730C207001950 @default.
• W2040797730 hasConceptScore W2040797730C2778707650 @default.
• W2040797730 hasConceptScore W2040797730C502942594 @default.
• W2040797730 hasConceptScore W2040797730C542903549 @default.
• W2040797730 hasConceptScore W2040797730C54355233 @default.
• W2040797730 hasConceptScore W2040797730C55493867 @default.
• W2040797730 hasConceptScore W2040797730C81885089 @default.
• W2040797730 hasConceptScore W2040797730C86803240 @default.
• W2040797730 hasConceptScore W2040797730C89423630 @default.
• W2040797730 hasConceptScore W2040797730C98274493 @default.
• W2040797730 hasIssue "7" @default.
• W2040797730 hasLocation W20407977301 @default.
• W2040797730 hasLocation W20407977302 @default.
• W2040797730 hasOpenAccess W2040797730 @default.
• W2040797730 hasPrimaryLocation W20407977301 @default.
• W2040797730 hasRelatedWork W1825374542 @default.
• W2040797730 hasRelatedWork W1971628265 @default.
• W2040797730 hasRelatedWork W1974845140 @default.
• W2040797730 hasRelatedWork W2009889818 @default.
• W2040797730 hasRelatedWork W2067193714 @default.
• W2040797730 hasRelatedWork W2072944349 @default.
• W2040797730 hasRelatedWork W2129233012 @default.
• W2040797730 hasRelatedWork W2368460920 @default.
• W2040797730 hasRelatedWork W2380360044 @default.
• W2040797730 hasRelatedWork W2433311123 @default.
• W2040797730 hasVolume "89" @default.
• W2040797730 isParatext "false" @default.
• W2040797730 isRetracted "false" @default.

• next